253 related articles for article (PubMed ID: 32659428)
21. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
22. Odd-chain fatty acids as novel histone deacetylase 6 (HDAC6) inhibitors.
Ediriweera MK; To NB; Lim Y; Cho SK
Biochimie; 2021 Jul; 186():147-156. PubMed ID: 33965456
[TBL] [Abstract][Full Text] [Related]
23. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
24. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
[TBL] [Abstract][Full Text] [Related]
25. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
26. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
[TBL] [Abstract][Full Text] [Related]
27. HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving α-tubulin acetylation.
Song R; Yang Y; Lei H; Wang G; Huang Y; Xue W; Wang Y; Yao L; Zhu Y
J Mol Cell Cardiol; 2018 Nov; 124():58-69. PubMed ID: 30315806
[TBL] [Abstract][Full Text] [Related]
28. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer.
Seidel C; Schnekenburger M; Mazumder A; Teiten MH; Kirsch G; Dicato M; Diederich M
Biochem Pharmacol; 2016 Jan; 99():31-52. PubMed ID: 26549368
[TBL] [Abstract][Full Text] [Related]
29. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
30. Rutin increases alpha-tubulin acetylation via histone deacetylase 6 inhibition.
Çetin Ö; Sari S; Erdem-Yurter H; Bora G
Drug Dev Res; 2022 Jun; 83(4):993-1002. PubMed ID: 35266183
[TBL] [Abstract][Full Text] [Related]
31. Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90).
Bonanni D; Citarella A; Moi D; Pinzi L; Bergamini E; Rastelli G
Curr Med Chem; 2022; 29(9):1474-1502. PubMed ID: 34477503
[TBL] [Abstract][Full Text] [Related]
32. A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells.
Won HR; Ryu HW; Shin DH; Yeon SK; Lee DH; Kwon SH
Mol Carcinog; 2018 Oct; 57(10):1383-1395. PubMed ID: 29917295
[TBL] [Abstract][Full Text] [Related]
33. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
34. Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90.
Liu P; Xiao J; Wang Y; Song X; Huang L; Ren Z; Kitazato K; Wang Y
Mol Med; 2021 Sep; 27(1):110. PubMed ID: 34530730
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
[TBL] [Abstract][Full Text] [Related]
36. Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells.
Kumar D; Sarma P; Bhadra MP; Tangutur AD
Anticancer Agents Med Chem; 2019; 19(6):750-759. PubMed ID: 30621566
[TBL] [Abstract][Full Text] [Related]
37. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Mahal K; Kahlen P; Biersack B; Schobert R
Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
[TBL] [Abstract][Full Text] [Related]
38. Drugging the HDAC6-HSP90 interplay in malignant cells.
Krämer OH; Mahboobi S; Sellmer A
Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862
[TBL] [Abstract][Full Text] [Related]
39. Acetylation/deacetylation and microtubule associated proteins influence flagellar axonemal stability and sperm motility.
Chawan V; Yevate S; Gajbhiye R; Kulkarni V; Parte P
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33200789
[TBL] [Abstract][Full Text] [Related]
40. Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.
Wu H; Yang K; Zhang Z; Leisten ED; Li Z; Xie H; Liu J; Smith KA; Novakova Z; Barinka C; Tang W
J Med Chem; 2019 Aug; 62(15):7042-7057. PubMed ID: 31271281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
